Advertisement
U.S. Markets open in 4 hrs 3 mins
S&P Futures
5,754.50 +16.00 (+0.28%) Dow Futures
42,024.00 +77.00 (+0.18%) Nasdaq Futures
20,101.75 +80.00 (+0.40%) Russell 2000 Futures
2,206.70 -1.90 (-0.09%) Crude Oil
71.30 +2.04 (+2.95%) Gold
2,763.30 +14.00 (+0.51%)
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 181.18 |
| Open | 178.11 |
| Bid | 165.53 x 100 |
| Ask | 184.92 x 100 |
| Day's Range | 173.88 - 179.48 |
| 52 Week Range | 173.88 - 268.30 |
| Volume | |
| Avg. Volume | 1,102,223 |
| Market Cap | 25.355B |
| Beta (5Y Monthly) | -0.06 |
| PE Ratio (TTM) | 15.72 |
| EPS (TTM) | 11.07 |
| Earnings Date | Oct 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 255.07 |
- Investing.com
Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
Investing.com -- Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204.
GuruFocus.comBiogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
Despite challenges in key segments, Biogen Inc (BIIB) raises EPS guidance and showcases promising growth in its rare disease franchise and pipeline potential.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.